In fact, the CHEK2 1100delC variant may explain up to 5% of BC families with a BRCA1/2 phenotype but with a BRCA1/2-negative test result, which has been shown to increase MBC risk by tenfold (Freitas et al. 2018; Tedaldi et al. 2020). This evidence concerns the gene CHEK2 and breast cancer.